TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s updated 2026 Antimicrobial Resistance Threats Report lists 19 pathogens at threat levels ranging from concerning to urgent, plus six on a watch list. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths in the United States each year.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens with threat levels ranging from concerning to urgent, and says the organisms collectively cause an estimated 9.7 million infections and 50,800 deaths in the United States each year. The agency also added six potential threats to a watch list, highlighting the continuing public health burden of infections that can resist available drugs.
Four drug-resistant pathogens are in the report’s urgent-threat category: Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC’s highest category signals pathogens that pose a serious public health risk and call for aggressive action, according to the report’s classification.
The report describes substantial effects from several of these organisms. In 2023, carbapenem-resistant Acinetobacter was linked to 9,497 U.S. hospitalizations and an estimated 817 deaths; carbapenem-resistant Enterobacterales were linked to 14,878 hospitalizations and an estimated 1,252 deaths. Those figures refer to the specific pathogens and year, rather than the total annual estimate for all organisms on the list.
Reported U.S. cases of Candida auris rose from 48 in 2016 to 4,523 in 2023. The yeast can cause severe infections, particularly among people who are already seriously ill. Drug-resistant N. gonorrhoeae presents a different challenge: it can make gonorrhea harder to treat. The report estimates that resistant gonorrhea caused 787,000 U.S. infections in 2023; 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations.
The Cost of Drug-Resistant Infections
The CDC’s combined estimate—50,800 deaths and 9.7 million infections annually—shows the scale of the threat across multiple pathogens, not a death toll attributed to one superbug. Resistance can narrow treatment choices and make infections more difficult to manage, with particular consequences for people receiving hospital or long-term care.
Wendy Armstrong, president of the Infectious Diseases Society of America, said drug-resistant infections can prolong hospital stays and raise health-care costs. She also warned that they can make it harder for doctors to safely provide other care, including cancer chemotherapy, organ transplants and surgeries. These are risks described by Armstrong, not outcomes established for every patient with a resistant infection.
The report also matters beyond hospitals. Drug-resistant gonorrhea can limit the antibiotics available to treat a common sexually transmitted infection. The CDC’s classification and estimates can help direct attention to prevention, monitoring and the development of new treatments, although the report itself does not guarantee that any particular response will reduce cases.
Products Worth Considering
EGO POWER+ LB6151 Cordless Leaf Blower with 2.5Ah Battery and Charger
EGO POWER+ HT2600 26-Inch Cordless Hedge Trimmer (Battery and Charger Not Included)
6×4 ft Walk-In Polycarbonate Greenhouse with Hygrometer
As an affiliate, we earn on qualifying purchases.
New Additions and Category Changes
The CDC’s 2026 report sorts pathogens into categories based on their public health threat and includes a separate watch list for potential threats. Six organisms joined that watch list, including drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria. The agency describes watch-list pathogens as having an uncertain disease burden that could make them potential threats.
One notable change is that Clostridioides difficile moved from urgent to serious. The source report says the change was driven in part by successful infection-prevention measures that have reduced cases since 2011. Drug-resistant Neisseria meningitidis was added to the serious-threat category, requiring prompt and sustained action, according to the report.
The report also arrives amid calls for federal support to develop antibiotics against resistant infections. Armstrong urged Congress to pass the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs for the most threatening pathogens and infections. The source report says versions of the bill remain stalled in congressional committees.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Annual Estimates
The report’s 9.7 million infections and 50,800 deaths are estimates covering the pathogens collectively. The supplied report summary does not break down that total by organism or specify the time window and calculation method behind the annual figures. Readers should not interpret the combined estimate as the number of deaths caused by the four urgent-threat pathogens alone.
Some individual figures are tied to 2023, including hospitalization, death and infection estimates, while the report was published in 2026. The source material does not provide current-year figures for each pathogen, or details on how cases may have changed since those measurements. It also does not give a full account of the evidence or criteria used to assign every pathogen its category.
The watch-list additions are identified as potential threats, but their future disease burden is uncertain. The report summary does not establish whether they will cause more infections or move into a higher threat category.
Monitoring and Drug Development
The CDC’s revised classifications put the named pathogens and potential threats in view for public health monitoring and response. The supplied report does not identify a specific next update date or announce a new intervention tied to the list.
In Congress, the next milestone for the PASTEUR Act would be movement out of committee; the source report says versions of the bill remain stalled there. Whether lawmakers will advance it, and what federal support for antimicrobial development would follow, is not clear from the available information.
Further detail on the report’s methods, pathogen-level estimates and response plans would help clarify how the annual total was calculated and how agencies intend to address the threats. Until then, the figures and categories should be read as the CDC’s current assessment, with some pathogen-specific data reflecting 2023.
Key Questions
What does the CDC estimate these pathogens cause each year?
The CDC estimates the pathogens covered by its updated report collectively cause 9.7 million infections and 50,800 deaths annually in the United States. Those totals are not assigned to any one pathogen in the supplied report summary.
Which pathogens are in the urgent-threat category?
The four named urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report says Clostridioides difficile moved from urgent to serious, driven in part by successful infection-prevention measures that have reduced case numbers since 2011.
What is the CDC watch list?
It identifies organisms considered potential threats with an uncertain disease burden. Six pathogens were included in the 2026 update, among them drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
What is the PASTEUR Act?
It is proposed federal legislation that would create a program to support development of antimicrobial drugs for threatening pathogens and infections. The source report says versions of the bill remain stalled in congressional committees.
Source: medpagetoday.com
